Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug monitoring of etoposide (VP16-213). I. A combined method of liquid chromatography and mass spectrometry.

Literature DB >> 2990749

Drug monitoring of etoposide (VP16-213). I. A combined method of liquid chromatography and mass spectrometry.

H Danigel, K H Pflüger, H Jungclas, L Schmidt, J Dellbrügge.

Abstract

Drug monitoring is performed by means of sample extraction, sample purification by high-performance liquid chromatography (HPLC), and sample detection by time-of-flight mass spectrometry. This mass spectrometry utilizing 252Cf fission fragment-induced ionization and desorption of nonvolatile compounds is suitable as a universal, nondestructive detector in HPLC. Liquid chromatography and mass spectrometry are combined, so that mass analysis can be operated online and offline to the fractional sampling of the effluent and the samples can still be recovered. As an alternative to HPLC separation, samples can be purified by thin-layer chromatography (TLC), resulting an offline TLC + MS combination. Preliminary pharmacokinetic data for etoposide (VP16-213) together with calibration data are presented, and are discussed with reference to the sensitivity and detection limit of the new experimental method.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 1985 PMID： 2990749 DOI： 10.1007/bf00257521

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

7 in total

1. Combined thin layer chromatography/mass spectrometry: an application of 252Cf plasma desorption mass spectrometry for drug monitoring.

Authors: H Danigel; L Schmidt; H Jungclas; K H Pflüger
Journal: Biomed Mass Spectrom Date: 1985-09

Review 2. The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors: P J Creaven
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

3. Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection.

Authors: J J Holthuis; F M Römkens; H M Pinedo; W J van Oort
Journal: J Pharm Biomed Anal Date: 1983 Impact factor: 3.935

Review 4. The podophyllotoxin derivatives VP16-213 and VM26.

Authors: B F Issell
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

5. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.

Authors: W E Evans; J A Sinkule; W R Crom; L Dow; A T Look; G Rivera
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

6. Pharmacokinetics of VP16-213 given by different administration methods.

Authors: M D'Incalci; P Farina; C Sessa; C Mangioni; V Conter; G Masera; M Rocchetti; M B Pisoni; E Piazza; M Beer; F Cavalli
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

7. High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma.

Authors: P Farina; G Marzillo; M D'Incalci
Journal: J Chromatogr Date: 1981-01-02

7 in total

5 in total

Review 1. Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors: J J Holthuis
Journal: Pharm Weekbl Sci Date: 1988-06-17

2. Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.

Authors: K H Pflüger; L Schmidt; M Merkel; H Jungclas; K Havemann
Journal: Cancer Chemother Pharmacol Date: 1987 Impact factor: 3.333